Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes.
Kristina L BajemaKristin BerryElani StrejaNallakkandi RajeevanYuli LiLei YanFrancesca CunninghamDenise M HynesMazhgan RownekiAmy BohnertEdward J BoykoTheodore J IwashynaMatthew L MaciejewskiThomas F OsborneElizabeth Marie VigliantiMihaela AslanGrant D HuangGeorge N IoannouPublished in: medRxiv : the preprint server for health sciences (2022)
Nirmatrelvir-ritonavir was highly effective in preventing 30-day hospitalization and death. Short-term benefit from molnupiravir was observed in older groups. Significant reductions in adverse outcomes from 31-180 days were not observed with either antiviral.